S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:MRSN

Mersana Therapeutics Stock Forecast, Price & News

$6.95
-0.82 (-10.55%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.86
$7.75
50-Day Range
$6.95
$9.86
52-Week Range
$6.86
$29.09
Volume
510,003 shs
Average Volume
789,054 shs
Market Capitalization
$499.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.44
30 days | 90 days | 365 days | Advanced Chart
Receive MRSN News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Mersana Therapeutics logo

About Mersana Therapeutics

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Headlines

Mersana Therapeutics (NASDAQ:MRSN) Hits New 52-Week Low at $7.06
November 26, 2021 |  americanbankingnews.com
Mersana Therapeutics (NASDAQ:MRSN) Reaches New 12-Month Low at $8.02
November 19, 2021 |  americanbankingnews.com
Mersana Therapeutics (NASDAQ:MRSN) Shares Gap Down to $9.61
November 9, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRSN
Fax
N/A
Employees
110
Year Founded
N/A

Sales & Book Value

Annual Sales
$830 thousand
Book Value
$2.16 per share

Profitability

Net Income
$-88.04 million
Net Margins
-348,653.50%
Pretax Margin
-348,653.50%

Debt

Price-To-Earnings

Miscellaneous

Free Float
68,101,000
Market Cap
$499.79 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/09/2021
Today
11/27/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/25/2022

MarketRank

Overall MarketRank

1.59 out of 5 stars

Medical Sector

1024th out of 1,392 stocks

Pharmaceutical Preparations Industry

487th out of 670 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

Is Mersana Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Mersana Therapeutics stock.
View analyst ratings for Mersana Therapeutics
or view top-rated stocks.

How has Mersana Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRSN stock has increased by 7.6% and is now trading at $6.95.
View which stocks have been most impacted by COVID-19
.

When is Mersana Therapeutics' next earnings date?

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, February 25th 2022.
View our earnings forecast for Mersana Therapeutics
.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) released its earnings results on Tuesday, November, 9th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.05. Mersana Therapeutics had a negative net margin of 348,653.50% and a negative trailing twelve-month return on equity of 77.17%. During the same quarter in the previous year, the company earned ($0.33) EPS.
View Mersana Therapeutics' earnings history
.

What price target have analysts set for MRSN?

5 equities research analysts have issued 1-year price objectives for Mersana Therapeutics' shares. Their forecasts range from $18.00 to $33.00. On average, they expect Mersana Therapeutics' stock price to reach $26.80 in the next twelve months. This suggests a possible upside of 285.6% from the stock's current price.
View analysts' price targets for Mersana Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the following people:
  • Anna Protopapas, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Brian DeSchuytner, Chief Financial Officer & Senior Vice President
  • Timothy B. Lowinger, Chief Science & Technology Officer (LinkedIn Profile)
  • Donna M. Jarlenski, Vice President-Clinical Operations
  • Arvin Yang, Chief Medical Officer & Senior Vice President

What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO?

3 employees have rated Mersana Therapeutics CEO Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among Mersana Therapeutics' employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mersana Therapeutics own?

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.27%), Wellington Management Group LLP (8.37%), Sarissa Capital Management LP (5.99%), Bellevue Group AG (5.94%), Rock Springs Capital Management LP (4.21%) and Candriam Luxembourg S.C.A. (2.82%). Company insiders that own Mersana Therapeutics stock include Andrew A F Hack, Anna Protopapas, Ashish Mandelia, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger.
View institutional ownership trends for Mersana Therapeutics
.

Which institutional investors are selling Mersana Therapeutics stock?

MRSN stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Millennium Management LLC, Two Sigma Investments LP, Assenagon Asset Management S.A., Deutsche Bank AG, Caption Management LLC, Citigroup Inc., and Allianz Asset Management GmbH. Company insiders that have sold Mersana Therapeutics company stock in the last year include Anna Protopapas, Ashish Mandelia, and Timothy B Lowinger.
View insider buying and selling activity for Mersana Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Mersana Therapeutics stock?

MRSN stock was acquired by a variety of institutional investors in the last quarter, including Bellevue Group AG, Goldman Sachs Group Inc., Morgan Stanley, Marshall Wace LLP, Sarissa Capital Management LP, First Manhattan Co., Rock Springs Capital Management LP, and Voloridge Investment Management LLC. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, and Lawrence M Alleva.
View insider buying and selling activity for Mersana Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $6.95.

How much money does Mersana Therapeutics make?

Mersana Therapeutics has a market capitalization of $499.79 million and generates $830 thousand in revenue each year. The company earns $-88.04 million in net income (profit) each year or ($2.14) on an earnings per share basis.

How many employees does Mersana Therapeutics have?

Mersana Therapeutics employs 110 workers across the globe.

What is Mersana Therapeutics' official website?

The official website for Mersana Therapeutics is www.mersana.com.

Where are Mersana Therapeutics' headquarters?

Mersana Therapeutics is headquartered at 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 498-0020 or via email at [email protected].


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.